Lowering LDL cholesterol reduces the risk of atherosclerotic vascular disease in a wide range of patients with chronic kidney disease, with no evidence of a threshold below which further reductions no longer reduce risk. Statins safely lower LDL cholesterol, but novel inhibitors of proprotein convertase subtilisin kexin 9 (PCSK9) provide additional reductions which may reduce atherosclerotic vascular disease yet further in this high risk population.

Original publication

DOI

10.1016/j.kint.2018.01.030

Type

Journal article

Journal

Kidney Int

Publication Date

06/2018

Volume

93

Pages

1267 - 1269